|
|||||
|
|
Phase II trial of docetaxel,bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer |
|
| Authors: | Ravi A. Madan Fatima H. Karzai Yang‐Min Ning Bamidele A. Adesunloye Xuan Huang Nancy Harold Anna Couvillon Guinevere Chun Lisa Cordes Tristan Sissung Shaunna L. Beedie Nancy A. Dawson Marc R. Theoret David G. McLeod Inger Rosner Jane B. Trepel Min‐Jung Lee Yusuke Tomita Sunmin Lee Clara Chen Seth M. Steinberg Philip M. Arlen James L. Gulley William D. Figg William L. Dahut |
| Affiliation: | 1. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA;2. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C., USA;3. Center for Prostate Disease Research, Walter Reed National Military Medical Center, Bethesda, MD, USA;4. Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA;5. Radiology and Imaging Sciences, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA |
| Abstract: | |
| Keywords: | prostate cancer angiogenesis inhibition combinationation therapy metastatic castration resistant prostate cancer docetaxel coimbination |